At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)drug
Likely dose
BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause
In Brief
A clinical study evaluating BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg) for Menopause. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a short supplementation (7days) with BASIS™ increases the natural production of estradiol, measured in urinary waste. The overall objective is to determine whether through increased estradiol levels, the undesirable menopausal effects, assessed via questionnaires, are mitigated by a short-term supplementation with BASIS™
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause
CountriesUnited States
CollaboratorsElysium Health, Inc.
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartApr 2021
First PostedApr 2021
Primary CompletionJul 2021
TodayJul 2026
First PostedApr 12, 2021
Enrollment StartApr 5, 2021
Primary CompletionJul 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.2 years ago
Interventions
BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)drug
take 2 capsules orally each day for 7 days